Prenatal vitamin D supplementation to prevent childhood asthma: 15-year results from the Vitamin D Antenatal Asthma Reduction Trial (VDAART)

J Allergy Clin Immunol. 2024 Feb;153(2):378-388. doi: 10.1016/j.jaci.2023.10.003. Epub 2023 Oct 16.

Abstract

This article provides an overview of the findings obtained from the Vitamin D Antenatal Asthma Reduction Trial (VDAART) spanning a period of 15 years. The review covers various aspects, including the trial's rationale, study design, and initial intent-to-treat analyses, as well as an explanation of why those analyses did not achieve statistical significance. Additionally, the article delves into the post hoc results obtained from stratified intent-to-treat analyses based on maternal vitamin D baseline levels and genotype-stratified analyses. These results demonstrate a statistically significant reduction in asthma among offspring aged 3 and 6 years when comparing vitamin D supplementation (4400 IU/d) to the standard prenatal multivitamin with vitamin D (400 IU/d). Furthermore, these post hoc analyses found that vitamin D supplementation led to a decrease in total serum IgE levels and improved lung function in children compared to those whose mothers received a placebo alongside the standard prenatal multivitamin with vitamin D. Last, the article concludes with recommendations regarding the optimal dosing of vitamin D for pregnant women to prevent childhood asthma as well as suggestions for future trials in this field.

Keywords: Vitamin D; childhood asthma; pregnancy; randomized trials; supplementation.

Publication types

  • Review

MeSH terms

  • Asthma* / prevention & control
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Dietary Supplements
  • Female
  • Humans
  • Pregnancy
  • Vitamin D* / therapeutic use

Substances

  • Vitamin D